Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Accumulated Expenses (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Accumulated Expenses for 4 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 3032.2% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 3032.2% year-over-year, with the annual reading at $1.5 million for FY2025, 3032.2% up from the prior year.
  • Accumulated Expenses hit $1.5 million in Q4 2025 for Coya Therapeutics, down from $1.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $3.0 million in Q4 2023 to a low of $46667.0 in Q4 2024.
  • Historically, Accumulated Expenses has averaged $1.0 million across 4 years, with a median of $842480.0 in 2024.
  • Biggest five-year swings in Accumulated Expenses: crashed 98.43% in 2024 and later skyrocketed 3032.2% in 2025.
  • Year by year, Accumulated Expenses stood at $135864.0 in 2022, then surged by 2088.38% to $3.0 million in 2023, then plummeted by 98.43% to $46667.0 in 2024, then surged by 3032.2% to $1.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for COYA at $1.5 million in Q4 2025, $1.6 million in Q3 2025, and $2.8 million in Q2 2025.